12:59 PM EDT, 05/13/2024 (MT Newswires) -- Jasper Therapeutics ( JSPR ) said Monday it is expanding the company's mast cell development portfolio and will evaluate briquilimab, a conditioning agent for patients undergoing stem cell transplant, in patients with asthma in phase 1b/2a study.

Enrolling in the study is expected to start in Q4, according to the company.

"We plan to present clinical data in the second half of 2025," Jasper President and Chief Executive Ronald Martell said.

The company shares were up 2% in recent trading.

Price: 21.76, Change: +0.43, Percent Change: +2.02